NYSE · TFX
Healthcare · Medical - Instruments & Supplies
$141.39
Down-$1.62 (-1.15%)
Updated Oct 31, 2026, 1:40 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · TFX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
TFX closed at $141.39 after 20 trading sessions, up 13.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $140.10 | $142.045 | $138.92 | $141.39 | 837.98K |
| Oct 28, 2026 | $138.03 | $140.30 | $136.92 | $138.98 | 630.14K |
| Oct 27, 2026 | $136.33 | $139.12 | $135.32 | $139.00 | 878.87K |
| Oct 26, 2026 | $134.36 | $138.064 | $130.48 | $136.80 | 683.01K |
| Oct 23, 2026 | $136.45 | $137.55 | $135.00 | $136.29 | 505.1K |
| Oct 22, 2026 | $132.30 | $137.015 | $131.265 | $136.58 | 697.97K |
| Oct 21, 2026 | $130.61 | $132.21 | $129.41 | $130.40 | 400.45K |
| Oct 20, 2026 | $130.51 | $131.886 | $129.40 | $131.15 | 485.09K |
| Oct 19, 2026 | $129.79 | $131.45 | $129.175 | $129.68 | 770.13K |
| Oct 16, 2026 | $130.14 | $131.21 | $128.685 | $130.43 | 838.28K |
| Oct 15, 2026 | $124.00 | $128.59 | $123.75 | $128.22 | 906.96K |
| Oct 14, 2026 | $123.86 | $124.89 | $123.11 | $123.29 | 706.51K |
| Oct 13, 2026 | $125.64 | $126.56 | $123.045 | $124.44 | 552.38K |
| Oct 12, 2026 | $124.74 | $126.81 | $123.735 | $125.70 | 621.42K |
| Oct 9, 2026 | $124.84 | $126.01 | $123.56 | $125.12 | 424.66K |
| Oct 8, 2026 | $124.02 | $124.95 | $122.0621 | $124.19 | 1M |
| Oct 7, 2026 | $125.07 | $126.84 | $122.84 | $124.48 | 928.3K |
| Oct 6, 2026 | $125.60 | $126.94 | $123.81 | $124.74 | 683.34K |
| Oct 5, 2026 | $124.52 | $127.435 | $123.23 | $125.24 | 561.64K |
| Oct 2, 2026 | $127.12 | $127.12 | $124.01 | $124.12 | 646.99K |
The latest Smart Investors Daily articles mentioning TFX.
Company
Market Activity
Research & News
TFX research
Company profile and research snapshot.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Truist Securities | Hold | — |
| Sep 28, 2026 | B of A Securities | Buy | — |
| Aug 25, 2026 | Needham | Buy | — |
| Aug 11, 2026 | UBS | Neutral | — |
| Aug 10, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
WAYNE, Pa., October 22, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI).
Yahoo · Oct 22, 2026
WAYNE, Pa., October 22, 2026--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5, 2026.
Benzinga · Oct 22, 2026
To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating diseases
Yahoo · Oct 20, 2026
Expanding reimbursement, telehealth integration, and AI-enabled wearables accelerate outpatient and home-based cardiac monitoring adoptionDublin, Oct. 20, 2026 (GLOBE NEWSWIRE) -- "U.S. Wireless Cardiac Monitoring Systems Market Size, Share & Trends Analysis Report by Test Type, Product Type, Indication, End Use, Payer Type, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. wireless cardiac monitoring systems market was valued at an estimated USD 2.4
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TFX.
